Expert commentary: The FINCH 1 and FINCH 3 trials - - European Congress of Rheumatology 2019; Madrid, Spain: 12–15 June | rheumatology.medicinematters.com
Skip to main content

Home

Latest news

Browse topics

Lupus
Rheumatoid arthritis
Spondyloarthropathies
COVID-19
Browse all topics

In focus

Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings

Conferences

ACR Convergence 2022
EULAR 2022 Congress

About us

Medicine Matters Rheumatology
EXTENDED SEARCH
Log in
Top

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 1 and FINCH 3 trials

share
SHARE
print
PRINT
insite
SEARCH

John Isaacs comments on the findings from the FINCH 1 and FINCH 3 trials and discusses how filgotinib might fit into the rheumatoid arthritis treatment landscape (2:56).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

share
SHARE
print
PRINT

Related content

15-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Expert commentary: The FINCH 3 trial

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The FINCH 1 trial

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Filgotinib beneficial for RA patients with no prior methotrexate exposure

13-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Support for filgotinib use in RA patients with inadequate response to methotrexate
Image Credits